The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
The 8,323-participant Lp(a)HORIZON trial did not demonstrate reduced cardiovascular risk in its overall population, according to September 4 disclosures. Detailed results are needed to interpret the gap between lowering the blood marker and improving clinical outcomes.
Retrospective coverage: A study published September 5, 2026 found an association between folic acid use and fewer new diabetes diagnoses. Its observational design cannot establish a preventive treatment benefit.
A September 5 mouse study adds evidence that the timing of growth-hormone signaling matters for aging. Human longevity benefits remain untested.
A September 4 study reported tumor-targeted immune responses after personalized peptide and DNA vaccines. This retrospective report explains why the early findings do not establish a survival benefit.
A mouse and cell study identifies citrate as a messenger connecting mitochondrial stress to lasting protective changes. Whether the pathway can safely improve resilience when activated in adulthood remains unknown.
Researchers found higher baseline DNA-damage signals and a distinct circulating cell-free DNA profile in frail older adults. The exploratory, cross-sectional results are not yet a validated blood test for frailty.
Removing a specialized dendritic-cell population—or disabling its antigen-presentation function—reduced CD8 T-cell accumulation and preserved brain tissue in a mouse model of tauopathy. Human tissue findings were observational, and the study did not test a treatment.
Researchers prevented persistent pain-related hypersensitivity in mice by disrupting a post-injury pathway that produces amyloid-beta 42 in the spinal cord. The findings identify a possible therapeutic target but do not show that anti-amyloid medicines prevent chronic pain in people.
A post hoc analysis of SPRINT and ACCORD-BP data associated a systolic target below 120 mm Hg with fewer cardiovascular events but more recorded kidney-function declines. The subgroup findings refine the risk discussion without establishing a universal treatment target.
Late-life treatment increased median lifespan by 12.4% in one mouse strain and preserved several measures of function. The study raises a testable longevity hypothesis but does not show that semaglutide slows aging or extends life in people.
A review of 38 randomized trials found substantial weight reductions with GLP-1 receptor agonists and newer multiagonists. Differences between studies prevented a formal pooled comparison, limiting claims that any experimental candidate outperforms established therapies.
Researchers linked an age-associated gut bacterium to healthier biomarker profiles in Chinese cohorts, then reported functional and inflammatory improvements after treating aged mice. The work identifies a testable microbiome pathway but provides no evidence that the bacterium or its metabolite slows aging in people.